Galantamine, developed by Janssen Pharmaceutical K.K., is positioned in the competitive landscape of Alzheimer's disease treatments, which includes established therapies such as donepezil and rivastigmine. The Phase 3 study aims to demonstrate the efficacy and safety of two fixed doses (16mg/day and 24mg/day) compared to placebo, potentially expanding its market share in a growing sector driven by increasing Alzheimer's prevalence. The successful completion of this trial may enhance Janssen's portfolio and provide a competitive edge, particularly if the results indicate significant improvements in cognitive function. Given the aging global population, the market for Alzheimer's treatments is expected to expand, making this asset a strategic focus for Janssen.